st. Fotievoy d10
(MEDEP Vaccination Center)
Telephones: +7 (495) 781-90-36; +7 (499) 685-00-17;
To sign up for vaccination in our clinic, you can leave a request on the site, and we will call you back yourself.
AD-M-toxoid (adsorbed diphtheria toxoid with a reduced antigen content) is a highly effective drug, a full course of vaccination creates a strong immunity in 95% of those vaccinated for 7-10 years. Mass production of diphtheria toxoid began in the 50s. Over the past decade, the quality of preparations containing purified diphtheria toxoid has been maintained at a high and stable level and meets the requirements of the WHO.
To obtain diphtheria toxoid, the method of acid-salt precipitation neutralized with formaldehyde and heating the toxin obtained by cultivating diphtheria pathogens is used.
AD-M-toxoid is a diphtheria toxoid adsorbed on aluminum hydroxide. The drug contains in 1 ml of 10 flocculating units (LF) of diphtheria toxoid. Preservative – merthiolate in a concentration of 0.01%.
AD-M-toxoid is intended for the prevention of diphtheria in children of sb-year-old age, adolescents and adults. AD-M-toxoid apply:
- For planned age-related revaccination of children aged 7 and 14 years if they had previously received an AC-toxoid in connection with the emergency prevention of tetanus. The drug is administered once.
- For immunization of adults (no age limit):
- vaccinated against tetanus less than 10 years ago in a planned manner. The drug is administered once;
- If it is known that adults have not previously been vaccinated against diphtheria, they should receive a full course of immunization (two vaccinations with AD-M-toxoid with an interval of 30 days and revaccination in 6–9 months). The next revaccination is carried out in 10 years with ADS-M-toxoid. AD-M-toxoid can be administered after a month or simultaneously with the polio vaccine and other preparations of the national vaccination calendar.
AD-M-toxoid is one of the least reactive drugs. Individual vaccinated in the first two days may develop short-term general (fever, malaise) and local (soreness, hyperemia, edema) reactions. In extremely rare cases, allergic reactions may develop (angioedema, urticaria, polymorphic rash), a slight exacerbation of allergic diseases. Considering the possibility of the development of immediate-type allergic reactions in particularly sensitive individuals, those vaccinated should be provided with medical observation for 30 minutes. Vaccination sites should be provided with anti-shock therapy. Persons who have been given the introduction of AD-M-toxoid severe forms of allergic reactions, further planned vaccinations of the drug is stopped.
Constant contraindications to the use of AD-M-toxoid in adults and children are absent. It is not recommended to conduct routine vaccinations for pregnant women. Persons who have experienced acute illness, are vaccinated 2–4 weeks after recovery. In milder forms of disease, diphtheria vaccination is allowed after the disappearance of clinical symptoms.
Patients with chronic diseases are vaccinated upon achieving complete or partial remission. Facial neurological changes are grafted after the progression of the process has ceased. Patients with allergic diseases are vaccinated 2–4 weeks after the end of the exacerbation, while the stable manifestations of the disease (localized skin manifestations, hidden bronchospasm, etc.) are not contraindications to vaccination, which can be carried out with appropriate therapy.
Immunodeficiencies, HIV infection, as well as supportive course therapy, including steroid hormones and psychopharmaceuticals, are not contraindications to vaccination.
Planned vaccinations with AD-M-toxoid are carried out no earlier than 1 month after vaccinations against other infections.
The tactics of vaccination with AD-M-toxoid premature babies, children who have had acute diseases, children with chronic diseases, as well as mild forms of respiratory and allergic diseases are similar to the tactics of immunization with DTP-vaccine.
Non-immune persons who are in the stage of exacerbation of chronic diseases and have direct contact with diphtheria patients (family, class, dormitory, etc.) may be vaccinated at the conclusion of a specialist before the onset of recovery (remission) with appropriate therapy.
AD-M-toxoid is released in 0.5 ml ampoules (one vaccination dose) and 1.0 ml each (two vaccination doses). The drug is stored in a dry, dark place at a temperature of 6 ± 2 ° C. Transportation is made by all types of covered transport under the same conditions. Shelf life of AD-M-toxoid – 3 years.
Diphtheria toxoid is also available as part of the DTP vaccine and in combination with tetanus toxoid (DTP and DTP-M).